- Home
- SEAT vs PCRX Comparison
SEAT vs PCRX Comparison
Compare SEAT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- PCRX
- Stock Information
- Founded
- SEAT 2001
- PCRX 2006
- Country
- SEAT United States
- PCRX United States
- Employees
- SEAT N/A
- PCRX N/A
- Industry
- SEAT Industrial Machinery/Components
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- PCRX Health Care
- Exchange
- SEAT Nasdaq
- PCRX Nasdaq
- Market Cap
- SEAT 366.2M
- PCRX 1.2B
- IPO Year
- SEAT N/A
- PCRX 2011
- Fundamental
- Price
- SEAT $1.93
- PCRX $23.31
- Analyst Decision
- SEAT Buy
- PCRX Buy
- Analyst Count
- SEAT 11
- PCRX 8
- Target Price
- SEAT $4.49
- PCRX $28.38
- AVG Volume (30 Days)
- SEAT 1.4M
- PCRX 537.5K
- Earning Date
- SEAT 08-05-2025
- PCRX 07-29-2025
- Dividend Yield
- SEAT N/A
- PCRX N/A
- EPS Growth
- SEAT N/A
- PCRX N/A
- EPS
- SEAT N/A
- PCRX N/A
- Revenue
- SEAT $748,757,000.00
- PCRX $702,772,000.00
- Revenue This Year
- SEAT N/A
- PCRX $7.54
- Revenue Next Year
- SEAT $4.42
- PCRX $10.78
- P/E Ratio
- SEAT N/A
- PCRX N/A
- Revenue Growth
- SEAT 0.82
- PCRX 3.08
- 52 Week Low
- SEAT $1.44
- PCRX $11.16
- 52 Week High
- SEAT $5.74
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- SEAT 54.56
- PCRX 37.20
- Support Level
- SEAT $1.82
- PCRX $22.82
- Resistance Level
- SEAT $2.06
- PCRX $23.83
- Average True Range (ATR)
- SEAT 0.14
- PCRX 0.67
- MACD
- SEAT 0.04
- PCRX -0.05
- Stochastic Oscillator
- SEAT 70.65
- PCRX 20.73
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.